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Abstract: The management of acute primary angle closure is directed at lowering the intraocular 
pressure and relieving pupil block. Conventional treatment involves the use of medical treatment 
and laser peripheral iridotomy, respectively, as a means for achieving these aims. Newer 
therapeutic strategies have been described that are potentially useful adjuncts or alternatives 
to conventional treatment. Emerging strategies that lower intraocular pressure include anterior 
chamber paracentesis, as well as laser procedures such as iridoplasty and pupilloplasty. A   possible 
alternative to relieving pupil block is lens extraction, and may be combined with adjunctive 
measures such as goniosynechiolysis and viscogoniosynechiolysis. Trabeculectomy has a limited 
role in the acute setting. This review paper reviews the current evidence regarding conventional 
and newer treatment modalities for acute primary angle closure.
Keywords: intraocular pressure, pupil block, anterior chamber paracentesis, iridoplasty, 
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Introduction
Acute primary angle closure (APAC) is an important cause of irreversible visual loss, 
particularly in East Asians in whom there is an incidence of 12.2 cases of APAC per 
100,000 per year reported in Singapore. The incidence is higher among Chinese people 
than in Malay or Indian people, in females, and those aged $60 years.1–3 APAC has 
serious long-term consequences and is potentially blinding. The timely management 
of an acute attack of primary angle closure (PAC) is important not only for prevent-
ing visual loss from the high-pressure episode but also for preventing progression 
to chronic angle closure glaucoma (CACG). A retrospective study has shown that, 
following resolution of an episode of APAC, 58.1% patients have raised intraocular 
pressure (IOP) requiring ocular hypotensive medications, with 32.7% eventually requir-
ing trabeculectomy.4 In the 4–10 years following an APAC attack, Aung et al reported 
that 18% of eyes had become blind, 48% of eyes had developed glaucomatous optic 
neuropathy, and 58% of eyes had vision worse than 20/40.5
The conventional practice in the management of APAC is to initially lower the IOP 
with topical and systemic medical therapy. This allows resolution of corneal edema 
and secondary inflammation, thereby enabling subsequent definitive treatment of the 
condition by relieving pupil block typically using laser peripheral iridotomy (LPI).6,7 
The goals of treatment are to lower IOP as quickly as possible in order to alleviate 
the suffering of the patient, reduce the risk of irreversible damage to the optic nerve 
head and other anterior segment structures, to prevent recurrent attacks and retard 
progression to CACG.8
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In this review paper, both the conventional and newer 
options in the management of APAC are discussed, with 
emphasis on methods of lowering IOP, techniques to relieve 
pupil block, and other adjunctive measures that may be useful 
alternatives in this condition.
Lowering IOP to allow resolution  
of the corneal edema
Conventional management
Medical treatment
Conventional medical treatment of IOP includes systemic 
medication such as hyperosmotic agents and carbonic 
anhydrase inhibitors as first-line treatment and various 
combinations of IOP-lowering agents, including topical 
beta-blockers, prostaglandin analogues, alpha-adrenergic 
agonists, and carbonic anhydrase inhibitors. Topical steroids 
are usually added to control intraocular inflammation. Once 
the IOP is lowered, pilocarpine can be used to constrict the 
pupil from its mid-dilated state and help pull the iris away 
from the iridocorneal angle.
In one study, the use of medical therapy alone (comprising 
a combination of intravenous acetazolamide followed by oral 
acetazolamide, as well as topical pilocarpine, timolol, and 
steroid drops) successfully aborted the episode of APAC 
within the first 24 hours in 89.2% of patients.9 However, 
this success rate is lower at preceding time points: 21.5% 
at 3 hours, 44.6% at 6 hours, and 76.2% at 12 hours. Given 
this slow rate of resolution, it has been argued that other 
techniques like anterior chamber paracentesis and argon laser 
peripheral iridoplasty (ALPI) may cause less damage to the 
optic nerve and other anterior segment structures by having 
a more rapid onset of action and quicker IOP reduction. 
Complications from medical therapy, though rare, can be 
potentially serious, such as metabolic acidosis and electrolyte 
disorders with acetazolamide10,11 and congestive cardiac 
failure with mannitol.7,9,12,13 Fortunately, the incidence of 
these complications is low and medical therapy still forms 
the mainstay of first-line therapy for APAC given its relative 
safety and efficacy.
Alternative strategies
Anterior chamber paracentesis
Anterior chamber (AC) paracentesis is an alternative method 
of lowering IOP in APAC and involves controlled drainage of 
aqueous from the anterior chamber by the use of a needle or 
incision with a blade. This can be performed using a slit lamp 
with the patient under topical anesthesia and aseptic conditions. 
AC paracentesis has the advantages of rapidly lowering IOP 
and being repeatable.7 With IOP lowered to adequate levels 
(albeit temporarily), corneal edema may clear enough to allow 
for earlier definitive treatment of pupil block with LPI.
The literature on this treatment modality is currently 
limited and mainly consists of descriptive case reports. This 
is possibly due to various technical difficulties, which will be 
elaborated upon further in this paper, as well as availability 
of other established effective treatments. A case series of ten 
eyes showed that AC paracentesis lowered IOP more   rapidly 
compared with eyes treated with conventional medical 
therapy, in which mean IOP dropped immediately from 
66.6 mmHg preparacentesis to 15.1 mmHg and 21.7 mmHg 
at 30 minutes postparacentesis.14 This was in comparison with 
the medication-only group, where mean IOP was 62.3 mmHg 
before treatment, dropping to 41.5 mmHg, 30 minutes after 
treatment. After 2 hours the IOP remained ,21 mmHg 
(comparable to eyes treated medically), although, beyond 
2 hours after paracentesis, IOP gradually drifted upward to 
levels comparable to the medication-only group; this is not 
unexpected since the procedure does not relieve pupil block. 
Hence, the benefits of AC paracentesis are short-lived and 
repeat treatment may be required. It may be best considered 
a temporizing measure until definitive treatment is instituted. 
Another case series looking at AC paracentesis used in 
conjunction with medical treatment for 14 cases of APAC and 
six cases of secondary glaucoma, found that IOP decreased 
from 53.4 mmHg preprocedure to 18.2 mmHg at 24 hours.15 
Relief of symptoms was seen in all patients, while corneal 
edema cleared in 17 cases; the three cases that failed came 
from the secondary glaucoma group. The authors reported 
no complications from the procedure.
An AC paracentesis must be undertaken with   caution.14 
The procedure may be technically challenging, due to both 
patient and ocular factors. The patient may be in great 
  discomfort with nausea or vomiting, and may not be able to 
cooperate with the procedure. Some, therefore, recommend 
performing the procedure under peribulbar local anesthesia. 
The AC may be extremely shallow, presenting the risk of 
damage to the surrounding iris, lens, or corneal endothelium. 
Malignant glaucoma may also result, due to rapid forward 
movement of the iris-lens diaphragm. Rapid decompression 
can precipitate a suprachoroidal hemorrhage or more com-
monly a decompression retinopathy or hyphema. Last but 
not least, as this is an intraocular procedure, the risk of 
endophthalmitis will always be present. Currently, this 
remains as an approach for patients for whom medical 
therapy is either unavailable or unsuitable, or for those that 
are approaching their maximal dosages for certain systemic 
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medications and still have unresolved APAC. If this fails to 
yield a clear cornea for LPI, then the next option would be 
to perform a surgical iridectomy.
ALPI and argon laser pupilloplasty
ALPI has been advocated in the management of APAC and 
has the weight of randomized controlled trials to support 
its use. It involves applying laser burns to the peripheral 
iris, causing contraction of the iris stroma and mechanically 
pulling the angle open, hence facilitating trabecular   aqueous 
drainage.7,16–18 ALPI has been reported to be a safe and 
effective alternative to medical treatment of APAC in a 
prospective randomized controlled trial.16 After initial 
treatment of topical timolol and pilocarpine, patients in this 
trial were randomized to either ALPI or medical treatment, 
which comprised systemic acetazolamide, as well as man-
nitol if the initial IOP was .60 mmHg. The study found 
that ALPI achieved lower IOPs at 15, 30, and 60 minutes 
after the institution of treatment. The duration of symptoms 
before treatment did not affect the efficacy of ALPI and, in 
long-term follow-up, there were no differences in mean IOP, 
the requirement for IOP-lowering agents, or the extent of 
peripheral anterior synechiae (PAS) between both groups. 
By changing the profile of the peripheral iris, ALPI may also 
remove a component of ciliary block.19
Another randomized controlled trial compared LPI alone 
to LPI with peripheral iridoplasty in patients with PAC and 
PAC glaucoma.18 The extent of PAS decreased significantly 
more in the combined LPI and iridoplasty group, compared 
with the LPI-alone group. There was no difference in IOP, 
need for medications and surgery, and visual function at 
1 year. As this study did not include patients who presented 
with APAC, these results may not be directly extrapolatable to 
our group of interest. Most of the studies on ALPI have been 
done on Asian eyes and ALPI is not widely used   elsewhere. 
This may be a reflection of the populations in which APAC 
is most common or the lack of evidence of its use in non-
brown irides.
ALPI offers the advantage of more rapid reduction in 
the IOP in the first few hours of the episode compared with 
conventional medical therapy. Further, it has been shown 
to reduce the formation of PAS (likely by cutting down the 
duration of appositional angle closure), thereby retarding 
the progression to CACG.16 In current practice, ALPI may 
not be widely accepted due to various difficulties associated 
with its use. Corneal clouding may pose technical difficulties. 
Also, there is a learning curve in the technique of performing 
ALPI, and as yet there are many different ways of  performing 
this. Another possible limitation, based on experience at our 
centre, is that APAC patients are often seen after office hours 
by more junior doctors who may not be sufficiently skilled in 
performing this procedure. There are no ideal laser param-
eters or number of spots required, and there is little evidence 
of its efficacy in eyes with significant PAS.20
Argon laser pupilloplasty is another technique that is 
useful in APAC where corneal clouding precludes LPI, 
and this may be used alone or in combination with other 
procedures such as ALPI to abort an acute attack.21 In this 
procedure, radial rows of laser contraction burns are applied 
to the pupillary border to cause pupil dilation. The burns may 
be performed around the entire circumference of the pupil to 
cause symmetrical dilation, or in a quadrant for focal dilation. 
Like ALPI, this is a temporizing measure to allow corneal 
edema to clear more quickly prior to LPI.
Corneal indentation (CI)
Indentation on the cornea can mechanically open the angle, 
forcing aqueous through the trabecular meshwork, thereby 
reducing IOP in APAC. It is a quick and readily available way 
of reducing IOP in the acute setting, particularly in situations 
where there is no access to medications or laser.22 Various 
tools have been used for corneal indentation, including 
muscle hooks, gonioprism lenses, cotton-tip applicators, and 
glass rods. Corneal indentation offers a controlled clearance 
of corneal edema before the relief of pupil block is attempted. 
The effect is short-lived, but the procedure is easy to perform, 
does not require expensive or complicated equipment, and is 
usually (though not always) effective.
The procedure itself is not standardized. Small case series 
describing the use and effect of corneal indentation have shown 
that most cases of APAC (presenting early and without PAS 
formation) respond well to corneal indentation after a short 
course of treatment (3–4 cycles of 30 seconds of pressure on, 
followed by pressure off) with any of the corneal indentation 
tools previously mentioned.23,24 The response to corneal inden-
tation seems independent of presenting IOP. Masselos et al23 
reported a case series of seven patients with six responding 
effectively to CI (three of whom were treated with indentation 
following failed medical therapy), while Teichman24 reported a 
case series of five patients studied over 8 months where corneal 
indentation was successful.
When performing indentation, it has been suggested that 
if using cotton-tip applicator/glass rod, the endpoint of inden-
tation is reached when the pupil margin moves. When using a 
gonioprism like the Zeiss 4 mirror lens (Carl Zeiss, Chester, 
VA), the endpoint is identified when the trabecular meshwork 
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is   visualized postindentation. Knowledge of these endpoints 
will prevent excessive pressure being applied to the cornea. 
It is recommended that indentation be performed over the 
inferior cornea to prevent damage to superior corneal epi-
thelium, thereby facilitating subsequent LPI. Masselos et al 
also found a possible association between the success of CI 
and LPI. Patients who failed to respond to CI with reduc-
tion in IOP were found to be refractory to subsequent LPI 
as well and it is postulated that CI may have a further role in 
predicting the effectiveness of LPI in patients, thus aiding in 
decision making regarding further treatment.23
There have been some concerns raised regarding the effect 
of raised IOP during the process of indentation causing isch-
emic damage to ocular tissues.23 However, the transient IOP 
increase during indentation has been found to be insufficient 
to cause permanent vascular disruption to the retina or optic 
nerve and no cases of optic nerve head infarction or retinal 
vascular occlusion were seen in the case series reported.23 
Corneal indentation can also be used in conjunction with any 
of the other procedures used for APAC.
Supine positioning of the patient
Lying the patient supine is recommended as it allows the lens-
iris diaphragm to move posteriorly with gravity, which may 
relieve some of the relative pupil block. This is particularly 
useful in such instances where there are multiple mechanisms 
involved and where there is zonular instability.
Corneal scraping
The edematous corneal epithelium, which may preclude a 
LPI, can be scraped off with a needle under topical anesthesia 
to create an area of clear cornea through which a LPI may 
be attempted.
Relieving pupil block
Once the IOP has been lowered sufficiently to allow corneal 
edema to clear and reduce the risk of ischemic damage to the 
optic nerve, definitive treatment to prevent recurrence of another 
acute attack must be performed. Definitive treatment involves 
overcoming the block at the level of the pupil, preventing aque-
ous from flowing from the posterior chamber to the anterior 
chamber. This is most commonly done by creating a conduit 
through the iris stroma either surgically (surgical iridectomy) 
or, more commonly, using a laser (LPI). In some cases removal 
of the lens can allow sufficient deepening of the anterior 
chamber to overcome the block. The fellow eye of APAC also 
requires prophylactic treatment with a laser PI, since half of 
these will otherwise suffer an acute attack within 5 years.6
Conventional treatment
LPI
In the past, surgical iridectomy was performed for APAC,25–28 
though in recent years LPI has become the treatment of choice, 
due to its non-invasive nature, ease of performing the procedure 
on an outpatient basis, and the low risk of complications.6
While Caucasian eyes usually benefit from LPI 
performed using neodymium-doped yttrium aluminium 
garnet (Nd:YAG) lasers alone, heavily pigmented irides 
have been shown to benefit from sequential argon laser and 
Nd:YAG laser which allows effective PI formation while 
minimizing tissue damage to the iris.29–31 In Caucasian eyes 
treated for APAC with LPI/surgical iridectomy, iridotomy 
alone is sufficient to control IOP 65%–76% of the time, and 
additional medical therapy can control the IOP in up to 84%–
99% of eyes. Furthermore, a prophylactic LPI is particularly 
effective in almost completely preventing an APAC attack in 
the fellow eye.32,33 In Asian eyes however, use of LPI alone 
does not guarantee good IOP control and a subsequent rise 
in IOP is seen in 76.6% of eyes within the first 6 months of 
the acute attack. Of all Asian eyes treated for APAC with 
LPI, 58.2% still require the use of additional antiglaucoma 
medication/filtration surgery to control IOP.32,33
Some cases of APAC may be refractory to treatment with 
LPI and the attack may remain unbroken. Cases where pupil 
block is not the mechanism of angle closure may not respond 
as well and still progress despite conventional treatment 
(for example, plateau iris).34 Performing LPI is still indicated 
in these cases as there may still be a component of pupil block. 
LPI may break some fine PAS, but the more established areas 
of PAS usually remain even after successful LPI despite the 
resultant angle widening. If the IOP remains persistently 
high, the formation of PAS or ultrastructural damage to the 
trabecular meshwork results in a compromised angle, which 
would predispose to CACG.
Although usually quite safe, LPI can occasionally be 
associated with complications including monocular diplopia, 
visual aberrations, bleeding/hyphema, IOP spikes, closure of 
the peripheral iridotomy due to pigmentary proliferation and 
corneal decompensation.35–38
Alternative strategies
Lens extraction
Primary lens extraction as treatment for APAC has been 
reported in many studies and can be considered as another 
modality in management.39–46 Lens extraction in APAC relieves 
pupil block and markedly decreases angle crowding, thus 
widening the angle.39,40 Ultrasound biomicroscopy shows that 
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cataract extraction results in angle widening and resolution of 
anterior-placed ciliary processes in PAC eyes.41
In cases of APAC where IOP is uncontrolled, lens 
extraction has been shown to result in good IOP control 
without medications in 67%–72% of cases.39 The greatest 
IOP reduction after lens extraction was seen in APAC eyes 
where IOP was uncontrolled preoperatively, compared with 
lens extraction performed for other non-acute angle closure 
eyes.42,43 A small case series of primary lens extraction for 
APAC examined the short-term effects on IOP.44 The authors 
of the series demonstrated a 9.0 mmHg drop in mean IOP 
on the first postoperative day and a 10.2 mmHg drop after 
the first postoperative week, compared with preoperative 
IOP of 22.8 mmHg. Other studies report IOP results in the 
longer term. Jacobi et al, for example, compared primary 
phacoemulsification and surgical iridectomy for treatment of 
APAC eyes and reported that glaucoma control was achieved 
in a significantly larger proportion in the phacoemulsification 
group (72% vs 35% respectively) and a lower proportion of 
this group required additional surgery (11.5% vs 63%).45 
Lam et al described the role of early phacoemulsification for 
APAC in a randomized controlled trial, where it was found 
that eyes undergoing LPI were 15 times more likely to have 
an IOP rise above 21 mmHg compared with eyes that had 
early phacoemulsification.46 At 18 months, the LPI group 
required more medications to control IOP compared with 
the phacoemulsification group.
However, lens extraction in an acute setting of APAC may 
pose technical difficulties during surgery (due to shallow 
anterior chamber depth, small pupils and/or floppy iris, intu-
mescent or subluxed lenses, and cornea edema) and postop-
erative complications such as corneal decompensation.40 Its 
popularity in APAC management has followed the techno-
logical advances in small-incision cataract surgery and the 
increasing expertise amongst the surgeons, making this option 
much more viable in recent times. Another consideration is the 
timing of lens extraction in an acute setting, weighing the need 
for acute IOP lowering as soon as possible against surgery in 
an inflamed edematous eye.40 Topical anesthesia may not be 
adequate in more inflamed eyes and there is the concern that 
surgery on an inflamed eye may result in more postoperative 
complications. These controversies are as yet unresolved and 
the optimum timing for lens extraction is unknown.
Adjunctive measures
While a significant number of cases of APAC respond well to 
medical therapy and subsequent LPI, presence of extensive PAS 
(usually more than 270° of closed angle) has a considerable 
negative impact on the success of this treatment modality 
and surgical intervention may be required.47 Traditionally, 
the failure of standard therapy was addressed with filtration 
surgery (trabeculectomy), possibly with combined lens extrac-
tion if warranted.48 While lens extraction alone has been 
shown to have some merit in treatment of unresponsive APAC 
patients,44,45 the benefits of addressing the PAS directly by per-
forming synechiolysis, either independently or in combination 
with cataract surgery before considering filtration surgery, have 
recently been brought to light.
Phacoemulsification of lens  
with intraocular lens (IOL) implantation
As already described, phacoemulsification and IOL 
implantation alone can be used to treat unresponsive APAC. 
In many cases, the procedure deepens the anterior chamber 
significantly and helps in breaking pupil block.44,45,49 
In addition, it has been shown that the surgical procedure 
itself as well as the use of viscoelastic to deepen the 
anterior chamber intraoperatively can cause breakdown of 
PAS to a certain extent (PAS .270°, reduced from 43% 
preoperatively to 24% postoperatively).50 In this same study, 
IOP decreased significantly from 19.7 mmHg preoperatively 
to 15.5 mmHg postoperatively. Treatment directed at breaking 
PAS was therefore possibly thought to be a useful way of 
treating refractory APAC.
Phacoemulsification  
with goniosynechiolysis
Goniosynechiolysis, a surgical procedure where the PAS are 
deliberately broken, has been reported to be effective for IOP 
control and reduction of synechiae in angle closure glaucoma, 
although to date there is limited literature on its use in the 
acute setting.51,52 It involves the physical stripping of PAS 
from the angle wall, thus restoring aqueous access to the 
trabecular meshwork. It is usually effective in patients with 
PAS present for ,6–12 months.51 It may be performed using 
surgical instruments or an Nd:YAG laser.51,52 Occasionally, 
gonioplasty using an argon laser is used in addition to the 
goniosynechiolysis in cases of extremely narrow angles.53
Goniosynechiolysis is effective when performed along 
or in conjunction with other surgical procedures. More 
commonly it is performed surgically in combination with 
phacoemulsification.52,54–57 After phacoemulsification, the 
anterior chamber is deepened with viscoelastic. The gonio-
synechiolysis can then be performed using a blunt Swan knife 
by applying posterior pressure to the angle structures under 
direct visualization with a goniolens; the end point being 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
421
Management of acute primary angle closureClinical Ophthalmology 2012:6
revisualization of the trabecular meshwork. For eyes with 
previous APAC and PAS, goniosynechiolysis combined with 
cataract extraction has been found to be more effective than 
goniosynechiolysis alone.54 In a prospective noncontrolled 
clinical trial in 52 eyes of 48 patients with APAC unrespon-
sive to LPI/ALPI, Teekhasaenee and Ritch reported 90.4% 
success (mean IOP ,20 mmHg without need for additional 
medication) and mean reduction of PAS from 310° to 60° 
with no recurrence of PAS up to 6 years.54 Harasymowycz 
et al performed a similar study using phacoemulsification 
with goniosynechiolysis with 21 patients who had acute or 
subacute angle closure glaucoma and showed a mean decline 
in IOP from 40.7 mmHg with 3.8 medications preoperatively 
to 15.5 mmHg with 1.7 medications over a mean follow-up 
of almost 1 year.55 After goniosynechiolysis, argon or diode 
laser peripheral iridoplasty can be used to further flatten the 
peripheral iris and prevent PAS reattachment.57,58
Complications of combined phacoemulsification with 
surgical goniosynechiolysis include fibrinoid anterior 
chamber reaction, photophobia, transient elevation of IOP 
(to .25 mmHg) and hyphema. Intraoperatively, there can 
also be mild to severe hemorrhage from the iris or trabeculum 
as well as iridodialysis.54,56
Phacoemulsification with 
viscogoniosynechiolysis
A further modification of phacoemulsification is the 
replacement of the surgical instrument by viscoelastic to 
perform the synechiolysis, which is less traumatic and 
results in fewer complications. Varma et al described 
the use of viscogonioplasty as adjunctive treatment after 
phacoemulsification, using viscoelastic injected around the 
angles to break PAS.47 In this case series of 15 patients, at 
6 months after surgery, mean IOP decreased from 52.1 mmHg 
to 14.1 mmHg, 14/15 were free of glaucoma medications, 
and the trabecular meshwork was exposed over 360° in all 
eyes with no residual synechiae.47
Razeghinejad et al described another case series of eleven 
APAC patients poorly responsive to medication and Nd:YAG 
laser iridotomy with up to 270° of PAS on indentation 
gonioscopy who were treated with phacoemulsification, 
IOL implantation, and viscosynechiolysis.59 They injected 
viscodispersive viscoelastic (hydroxypropyl methylcel-
lulose 2%) near the angle after IOL implantation to divide 
the synechiae without contact with adjacent angle or iris. 
Mean follow-up of 7–8 months showed dramatic decline 
in mean IOP (down from 39.4 ± 10.8 mmHg to a mean of 
13.4 ± 2.9 mmHg), reduced need for additional antiglaucoma 
medication (3.8 ± 0.7 preoperatively to 0.4 ± 0.9), and none of 
the patients required further filtration surgery. PAS resolved in 
all but one patient postsurgery. Importantly, the intraoperative 
and postoperative complications – for example, hemorrhage, 
iridocyclodialysis, and so forth – normally described with 
surgical goniosynechiolysis were not observed in this series, 
which suggests that this procedure is safer. However, critics 
may argue that simple viscoelastic is not strong enough to 
remove the more established, adhesive segments of PAS.
Trabeculectomy/phacotrabeculectomy
Filtration surgery in the form of trabeculectomy alone or 
combined cataract extraction is occasionally used as the 
final step in the management of APAC, when the condition 
has been refractory to all other modalities of treatment. 
Primary trabeculectomy early in APAC has several associ-
ated complications given the hot and inflamed nature of the 
eye being operated upon, including shallow or flat anterior 
chamber, malignant glaucoma, suprachoroidal hemorrhage, 
and endophthalmitis.60
In a study of trabeculectomy in patients with medically 
unresponsive APAC, success (defined as reducing IOP 
to ,22 mmHg) was as low as 56.2% compared with a 
success rate of 70%–95% when trabeculectomy is used 
conventionally for treatment of a quiet eye with CACG.61 
Eyes with APAC that responded to medical treatment but 
had other signs suggesting CACG showed a better response 
to trabeculectomy with decline in IOP in about 87.5% of 
cases. In this study, these eyes did not receive LPI prior 
to the trabeculectomy. There are still insufficient data to 
determine whether an eye with APAC and signs of CACG 
is better treated with primary LPI or a primary trabeculec-
tomy. The indication for performing trabeculectomy surgery 
may include those that had an acute on chronic type of 
presentation, where there was already extensive damage to 
the optic nerve and/or the persistence of high IOP after other 
treatments such as LPI.
The possible complications of trabeculectomy are numerous 
and can be sight threatening with serious consequences, which 
include postoperative cataract progression, hypotony with resul-
tant maculopathy, bleb leak, blebitis, and endophthalmitis.62,63 
The use of adjunctive antifibrotic agents such as mitomycin 
C may lead to increased risk of complications, including 
endophthalmitis, overfiltration, and hypotony.64–68
Conclusion
The conventional management of APAC involves systemic 
and topical medical treatment followed by LPI, though newer 
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methods in the form of ALPI and primary lens extraction may 
offer some benefits, especially where medical treatment is 
inadequate or unsuitable. Other methods of breaking the initial 
attack, such as AC paracentesis and corneal indentation, merit 
some thought as they provide simple, quick, and effective 
alternatives to medical therapy, particularly in primary 
care settings. Patients with APAC refractive to medical 
therapy/LPI and those who have other signs of CACG and 
extensive PAS may require more extensive therapy.   Breaking 
the PAS by goniosynechiolysis and viscogonioplasty in 
isolation or in combination with cataract extraction are useful 
adjunctive measures. Filtration surgery still remains the final 
resort and may be useful as the primary surgical intervention 
in some patients with signs of advanced acute on chronic 
CACG, but further studies are needed to determine their 
usefulness as a primary procedure.
While there exist an armamentarium of treatment 
strategies for the management of APAC, the conventional 
treatment of medications and LPI has a track record of 
efficacy. Other modalities may be considered where 
conventional treatment fails. Further research is required 
to evaluate the different management strategies for this 
condition which is potentially blinding.
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